EE320 Cost-Effectiveness of Glofitamab vs Chemoimmunotherapy Regimens for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RRDLBCL) After at Least Two Lines of Systemic Therapy in the Czech Republic
Abstract
Authors
S Motylova J Dolezel J Novák M Pour K Krihova D Skalicky